Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2negative advanced breast cancer
the choice depends on whether the work calls for fixed co-administration or independent dosing
Belangrijke mededeling: Dit product is uitsluitend bestemd voor onderzoeks- en laboratoriumgebruik
With a focus on providing holistic and personalized care, our clinic combines various treatment modalities to support individuals with muscular dystrophy in their journey toward improved mobility and enhanced quality of life
Open Biol 14:240035
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
